Why the study?
Recent clinical trials such as ISCHEMIA have drastically changed the approach to stable coronary artery disease, yet unresolved and unmet issues remain in Asia where prevalence and practice patterns differ from Western countries.
This review discusses updated diagnostic and therapeutic strategies for stable coronary artery disease following the ISCHEMIA trial, with a specific focus on unmet needs and practice patterns in Asian populations.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to Asia-specific gaps in stable CAD care post-ISCHEMIA; leaves open targeted trials to refine regional strategies.
Until recently, coronary revascularization with coronary artery bypass grafting or percutaneous coronary intervention has been regarded as the standard choice for stable coronary artery disease (CAD), particularly for patients with a significant burden of ischemia. However, in conjunction with remarkable advances in adjunctive medical therapy and a deeper understanding of its long-term prognosis from recent large-scale clinical trials, including ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), the approach to stable CAD has changed drastically. Although the updated evidence from recent randomized clinical trials will likely modify the recommendations for future clinical practice guidelines, there are still unresolved and unmet issues in Asia, where prevalence and practice patterns are markedly different from those in Western countries. Herein, the authors discuss perspectives on: 1) assessing the diagnostic probability of patients with stable CAD; 2) application of noninvasive imaging tests; 3) initiation and titration of medical therapy; and 4) evolution of revascularization procedures in the modern era.
No takes yet. Share an insight, caveat, or question.
Kohsaka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: